Cardiovascular

Latest News
July 28th 2025

Pediatric Hypertension Increasing Among Children, Adolescents Worldwide

July 17th 2025

Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

July 14th 2025

Delayed Hypertension Diagnosis Tied to Higher Cardiovascular Risk, Lower Treatment Rates

June 19th 2025

40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death

June 3rd 2025

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

AJMC Peer Exchange logo
Video Interviews
View All
August 3rd 2025

DETECT AS Trial Shows Notification System Closes Care Gaps: Varsha Tanguturi, MD

August 3rd 2025

TikTok's Role in Shaping Cholesterol Knowledge: Khush Kharidia, MD

August 1st 2025

Disparities in Pregnancy-Related Hypertension Among Hispanic Subgroups: Alexandra M. Trevino, MD

July 6th 2025

Improving Value in Cardiovascular Care Starts With More Accurate Testing: Merrill Stewart, MD

July 1st 2025

GME Funding Is Crucial to Addressing the Physician Shortage: Merrill Stewart, MD

June 26th 2025

Using Video Education to Boost Patient Engagement in Echocardiography: Merrill Stewart, MD

June 18th 2025

Cost and Infrastructure Slow Cardiac PET Adoption: Merrill Stewart, MD

June 9th 2025

Not All Coronary Blockages Need Fixing: Merrill Stewart, MD

June 3rd 2025

How Can PET Cardiac Stress Testing Prevent Invasive Procedures? Merrill Stewart, MD

May 12th 2025

Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Podcasts
View All
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

February 22nd 2020

Podcast: This Week in Managed Care—Setbacks for Medicaid Work Rules and Other Health News

June 2nd 2019

Podcast: This Week in Managed Care—The $2 Million Gene Therapy and Other Health News

December 1st 2018

Podcast: This Week in Managed Care—CMS Drug Coverage Changes Draw Ire and Other Health News

November 18th 2018

Podcast: This Week in Managed Care—Cancer Is the New Leading Cause of Death and Other Health News

November 10th 2018

Podcast: This Week in Managed Care—Medicaid Expansion at the Ballot Box and Other Health News

June 17th 2017

Podcast: This Week in Managed Care - Dropped ACA Coverage, and Other News

Continuing Medical Education
View All
August 3rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 3rd 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology
August 3rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
August 3rd 2025

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

1.5 Credits / Cardiology
August 3rd 2025

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

1.5 Credits / Cardiology, Rare Diseases
August 3rd 2025

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

1.5 Credits / Pulmonology, Cardiology, Rare Diseases

More News

CBD oils and hemp leaves | Image credit: Irina_Evva – stock.adobe.com
May 23rd 2025

CBD-Based Drug Shows No Heart Safety Risks in Patients With CVD or Risk Factors

Hayden E. Klein
A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.
AJMC
May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD
This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Doctor taking child's blood pressure | Image credit: romaset – stock.adobe.com
May 14th 2025

3 Maternal Risk Factors Linked to Elevated Offspring Blood Pressure

Hayden E. Klein
Offspring born to mothers with prepregnancy obesity, gestational diabetes, or hypertensive disorders of pregnancy had higher systolic and diastolic blood pressure levels than those born to mothers without these risk factors.
Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models
May 12th 2025

Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss lessons learned from implementing lipid-lowering therapy recommendations and explore the role value-based care models may play in successfully adopting the National Lipid Association’s (NLA) recommendation for lipoprotein(a) (Lp[a]) testing.
Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience
May 12th 2025

Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss lessons learned from implementing lipoprotein(a) (Lp[a]) testing in health care systems, how health systems can prioritize patients for testing based on the National Lipid Association’s (NLA) recommendation, the role of integrated delivery networks in helping providers identify priority patients, and strategies for adding electronic health record alerts for Lp(a) testing.
Nurse using stethoscope on older patient | Image credit: InsideCreativeHouse – stock.adobe.com
May 9th 2025

Is Frailty Index the Most Accurate Predictor of CVD?

Hayden E. Klein
A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.
Antoine Keller, MD
May 9th 2025

Striving for Health Equity: Antoine Keller, MD

Kyle Munz Antoine Keller, MD, FACC, FACS
Antoine Keller, MD, argued the value of grounding health care policy in equity as clinicians prepare for a changing health care landscape in the coming years.
Effect of Remote Patient Monitoring on Stage 2 Hypertension
May 6th 2025

Effect of Remote Patient Monitoring on Stage 2 Hypertension

Lyle Dennis, MD Irina Koyfman, DNP, NP-C, RN
A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential benefits of RPM with care coaching.
Antoine Keller, MD
May 6th 2025

Technological Advances in CV Care Depend on Human Resources: Antoine Keller, MD

Kyle Munz Antoine Keller, MD, FACC, FACS
Antoine Keller, MD, discussed the future impact of technological advances for cardiovascular (CV) care and what other elements contribute to quality, accessible health care.
Lp(a) Testing: Prevalence and Strategies to Improve Uptake
May 5th 2025

Lp(a) Testing: Prevalence and Strategies to Improve Uptake

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its commonality within health plans, and how payers, population health decision makers, and provider groups can integrate Lp(a) testing into broader population health management strategies.
Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
May 5th 2025

Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.
The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
April 28th 2025

The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss how lipoprotein(a) (Lp[a]) testing, even without targeted Lp(a)-lowering therapies, can enhance overall cardiovascular risk assessment and potentially influence the management of other risk factors.
FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
April 28th 2025

FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss FDA-approved therapies for high lipoprotein(a) [Lp[a]) levels, their benefits and shortcomings, the frequency of their use in health plans, emerging therapies in the pipeline, and the expected timeline for associated data release.
Q&A with Sid Patel, MD
April 24th 2025

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

Kyle Munz Siddharth M. Patel, MD, MPH
The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.
Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing
April 21st 2025

Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the cost of lipoprotein(a) (Lp[a]) tests and how these costs, along with the National Lipid Association’s (NLA) recommendation and supporting clinical evidence, may influence payer decisions regarding coverage for Lp(a) testing.
Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
April 21st 2025

Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss whether providers should wait for another complete scientific statement from the National Lipid Association (NLA) or new guidelines from organizations like the American Heart Association (AHA) before implementing the 2024 NLA recommendation for universal lipoprotein(a) (Lp[a]) measurement.
One's ZIP code can greatly influence care access | image credit: Syda Productions - stock.adobe.com
April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

Kyle Munz Antoine Keller, MD, FACC, FACS
Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Evidence Supporting 2024 Guidance for Lp(a) Testing
April 14th 2025

Evidence Supporting 2024 Guidance for Lp(a) Testing

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the evidence supporting the National Lipid Association’s (NLA) recommendation for universal lipoprotein(a) (Lp[a]) measurement and evaluate how compelling this evidence is from a clinical perspective.
The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
April 14th 2025

The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss how guideline recommendations influence formulary decisions regarding preventive measures like lipoprotein(a) (Lp[a]) testing, exploring the varying recommendations from organizations such as the American Association of Clinical Endocrinologists, the American Heart Association, and the National Lipid Association (NLA), and how these align with recent guidance from Europe and Canada.
Joseph Saseen, PharmD
April 10th 2025

Lp(a) Awareness Imperative for Enhancing Testing, Prevention Efforts in CVD: Joseph Saseen, PharmD

Kyle Munz Joseph J. Saseen, PharmD
Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected.
Jeremy Wigginton, MD
April 8th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

Kyle Munz Jeremy Wigginton, MD
Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
April 7th 2025

A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss an example illustrating the association between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk and explore how this example can inform our understanding of Lp(a) and ASCVD risk on a population level.
How the Genetic Nature of Lp(a) Levels Influences Screening
April 7th 2025

How the Genetic Nature of Lp(a) Levels Influences Screening

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the genetic determinants of lipoprotein(a) (Lp[a]) levels, providing evidence supporting this conclusion. They also explore how the hereditary nature of Lp(a) can drive awareness of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis risk, potentially influencing screening protocols.
ACC.25
April 4th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

Giuliana Grossi Christian Ruff, MD John Buse, MD, PhD Marc P. Bonaca, MD, MPH Marc Humbert, MD, PhD Jawad Haider Butt, MD, PhD Siddharth M. Patel, MD, MPH
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Heart disease is, and has been, the number 1 cause of death for Americans over the last century | image credit: Thirakun - stock.adobe.com
April 2nd 2025

Digital Solutions Can Transform CVD Care, Prevention

Kyle Munz
Mobile self-management programs like that offered by Hello Heart can benefit employers and patients alike as they seek to manage and prevent heart disease.
Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
March 31st 2025

Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the evidence supporting the continuous relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD), as recognized by the National Lipid Association, and explore how Lp(a) levels may change throughout a person’s lifetime or in response to lifestyle factors.
Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
March 31st 2025

Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

Nihar Desai, MD, MPH Nathan Wong, PhD Jeremy Wigginton, MD, MBA, FAAFP Joseph Saseen, PharmD, BCPS, BCACP, CLS Jaime E. Murillo, MD
Experts discuss the relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk, with findings from a large US population study, and explore how these findings could impact clinical practice and the management of patients at risk for ASCVD.
Jaime Murillo, MD
March 29th 2025

AI Is Changing the Landscape of Cardiovascular Care

Kyle Munz Jaime Murillo, MD
Implementing artificial intelligence (AI) has transformed clinicians' and health systems' ability to screen for and distinguish forms of cardiorenalmetabolic disease.
Improving Cardiovascular Treatment Adherence Through Education, Engagement
March 26th 2025

Improving Cardiovascular Treatment Adherence Through Education, Engagement

Kyle Munz Jaime Murillo, MD
Jaime Murillo, MD, discusses the importance of fostering open communication with patients as a means of encouraging adherence to various treatments.
Nathan Wong, PhD
March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD
Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.
12345678
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo